RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells

Molecular and Cellular Biochemistry

Volumn 350, Issue 1-2, 2011, Pages 193-200

  Li, Guilin ^a   Wang, Renzhi ^a   Gao, Jun ^a   Deng, Kan ^a   Wei, Junji ^a   Wei, Yanping ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NONE

Author keywords

Cell cycle arrest; Cell proliferation; Human glioblastoma cells; iASPP; RNA interference

Indexed keywords

CYCLIN D1; DNA; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS STIMULATING PROTEIN OF P53; LENTIVIRUS VECTOR; PROTEIN P21; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; LENTIVIRINAE; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; REPRESSOR PROTEINS; RNA INTERFERENCE;

LENTIVIRUS;

EID: 79953693249     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-010-0698-9     Document Type: Article

References (34)

1. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG (2006) Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist 11:165-180 (Pubitemid 43261763)
2. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I, Tomlinson ML, Kuwabara PE, Lu X (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33:162-167 (Pubitemid 36177067)
3. Yang JP, Hori M, Takahashi N, Kawabe T, Kato H, Okamoto T (1999) NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 18:5177-5186 (Pubitemid 29460653)
4. Yang JP, Hori M, Sanda T, Okamoto T (1999) Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor. J Biol Chem 274:15662-15670
5. Trigiante G, Lu X (2006) ASPPs and cancer. Nat Rev Cancer 6:217-226 (Pubitemid 43292565)
6. Slee EA, Lu X (2003) The ASPP family: deciding between life and death after DNA damage. Toxicol Lett 139:81-87 (Pubitemid 36298965)
7. Zhang X, Wang M, Zhou C, Chen S, Wang J (2005) The expression of iASPP in acute leukemias. Leuk Res 29:179-183 (Pubitemid 39647513)
8. Liu ZJ, Cai Y, Hou L, Gao X, Xin HM, Lu X, Zhong S, Gu SZ, Chen J (2008) Effect of RNA interference of iASPP on the apoptosis in MCF-7 breast cancer cells. Cancer Invest 26:878-882
9. Mori T, Okamoto H, Takahashi N, Ueda R, Okamoto T (2000) Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett 465:124-128 (Pubitemid 30021458)
10. Lage H (2005) Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 1:103-113
11. Abdelrahim M, Safe S, Baker C, Abudayyeh A (2006) RNAi and cancer: implications and applications. J RNAi Gene Silen 2:136-145
12. Singh A, Boldin-Adamsky S, Thimmulappa RK, Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F, Watson WH, Gabrielson E, Feinstein E, Biswal S (2008) RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68:7975-7984
13. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553 (Pubitemid 34408678)
14. Nishitsuji H, Ikeda T, Miyoshi H, Ohashi T, Kannagi M, Masuda T (2004) Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. Microbes Infect 6:76-85 (Pubitemid 38114824)
15. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:401-406 (Pubitemid 36278858)
16. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, MacGregor RR, June CH, Dropulic B (2005) Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 16:17-25 (Pubitemid 40250328)
17. Bank A, Dorazio R, Leboulch P (2005) A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 1054:308-316 (Pubitemid 43031038)
18. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA, Novina CD (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:493-501 (Pubitemid 36356735)
19. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408 (Pubitemid 34164012)
20. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
21. Rasola A, Geuna M (2001) A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry 45:151-157 (Pubitemid 32954245)
22. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310
23. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355 (Pubitemid 24259959)
24. Liu ZJ, Zhang Y, Zhang XB, Yang X (2004) Abnormal mRNA expression of ASPP members in leukemia cell lines. Leukemia 18:880 (Pubitemid 38500212)
25. Bögler O, Huang HJ, Kleihues P, Cavenee WK (1995) The p53 gene and its role in human brain tumors. Glia 15:308-327
26. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 3:229-235 (Pubitemid 23276689)
27. Frankel RH, Bayona W, Koslow M, Newcomb EW (1992) p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52:1427-1433
28. Morgan DO (1995) Principles of CDK regulation. Nature 374:131-134
29. Ball KL (1997) p21: structure and functions associated with cyclin-CDK binding. Prog Cell Cycle Res 3:125-134
30. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944
31. Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G (1994) Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 9:1633-1640 (Pubitemid 24163389)
32. Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79:551-555
33. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY (1994) D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066-2076 (Pubitemid 24074604)
34. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, Sherr CJ (1992) Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71:323-334